Skip to main content

Table 2 Overall survival for different patient groups in Study 301

From: “New” metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy

  Progression due to new metastases Progression due to pre-existing lesions No reported disease progression
  Eribulin Capecitabine Total Eribulin Capecitabine Total Eribulin Capecitabine Total
  (n = 216) (n = 204) (N = 420) (n = 131) (n = 112) (N = 243) (n = 207) (n = 232) (N = 439)
Median OS, months (95 % CI) 14.6 (12.4, 17.1) 11.3 (9.2, 13.4) 13.0 (11.6, 14.4) 18.0 (14.7, 19.7) 16.7 (14.2, 19.9) 17.1 (15.5, 19.4) 17.6 (15.4, 20.7) 16.8 (14.3, 19.1) 16.9 (15.7, 18.9)
HR eribulin vs. capecitabine (95 % CI) 0.75 (0.61, 0.93) 0.92 (0.69, 1.23) 0.91 (0.73, 1.15)
p value 0.008 0.57 0.44
  1. Progression events were determined by independent review
  2. CI confidence interval, HR hazard ratio, OS overall survival